ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting

    Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study

    Ajinkya Pawar 1, Rishi Desai 1, Nileesa Gautam 1 and Seoyoung C. Kim2, 1Brigham and Women's hospital, Boston, 2Brigham and Women’s Hospital and Harvard Medical School, Boston

    Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
  • Abstract Number: 1229 • 2018 ACR/ARHP Annual Meeting

    Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis

    Serene Z. Mirza1, Shawn Richardson2, Cynthia Kahlenberg2, Jason Blevins2, Michelle Demetres3, Lily Martin3, Jackie Szymonifka2, Peter K. Sculco4, Mark P. Figgie5 and Susan M. Goodman2, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Weill Cornell Medicine, New York, NY, 4Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Surgery, Hospital for Special Surgery, New York, NY

    Background/Purpose: Patients with inflammatory arthritis (IA) are at increased risk of prosthetic joint infections, yet differentiating between septic and aseptic failure is a  challenge in…
  • Abstract Number: 2832 • 2018 ACR/ARHP Annual Meeting

    Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2

    Sheng-Xiao Zhang1, Xiao-Yan Wu2, Jing Luo3, Guang-Ying Liu2, Chong Gao4, Cai-Hong Wang5 and Xiao-Feng Li5, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 3the Second Hospital of Shanxi Medical University, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 5The Second Hospital of Shanxi Medical Univerity, Taiyuan, China

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of intrinsic or adaptive immune system…
  • Abstract Number: 1231 • 2018 ACR/ARHP Annual Meeting

    Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS

    Jorge Juan Fragio Gil1, Roxana Gonzalez Mazario1, Francisco Miguel Ortiz-Sanjuán1, Jose Ivorra Cortes1, Elena Grau Garcia1, Karla Arevalo1, Isabel Martinez Cordellat1, Inmaculada Chalmeta Verdejo1, Jose Eloy Oller Rodriguez1, Luis Gonzalez Puig1, Marta De la Rubia Navarro1, Rosa Negueroles Albuixech1, Cristina Alcañiz Escandell2, Elvira Vicens Bernabeu1, Eva Calabuig3, Maria Tasias Pitarch3, Miguel Salavert Lleti3 and Jose Andres Roman Ivorra1, 1Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2IIS La Fe, Valencia, Spain, 3Infectious Diseases Unit. Hospital Universitario y Politecnico La Fe, Valencia, Spain

    Background/Purpose: Vertebral Osteomyelitis is an infectious disease of the vertebral body which could involve the intervertebral space (spondylodiscitis). Early diagnosis and treatment are essential in…
  • Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting

    Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System

    Sarah L. Patterson1, Michael Evans2, Ishita Aggarwal3, Zara Izadi4, Milena Gianfrancesco5, Gabriela Schmajuk6 and Jinoos Yazdany7, 1Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2University of California - San Francisco, San Francisco, CA, 3Medicine, Santa Clara Valley Medical Center, San Jose, CA, 4Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 5Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6San Francisco VA Medical Center, San Francisco, CA, 7University of California, San Francisco, San Francisco, CA

    Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
  • Abstract Number: 218 • 2018 ACR/ARHP Annual Meeting

    Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients

    Yinzhu Jin1, Eun Ha Kang2, Rishi J. Desai3, Angela Tong1 and Seoyoung C. Kim4,5, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), 3Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Treatment with tumor necrosis factor inhibitor (TNFi) with methotrexate or triple therapy (MTX, sulfasalazine, and sulfasalazine) is considered in patients with rheumatoid arthritis (RA)…
  • Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting

    Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study

    Raul Castellanos-Moreira Sr.1, Sebastian C Rodriguez-Garcia1, M. Victoria Hernández2, Virginia Ruiz-Esquide3, Oscar Camacho Sr.1, Andrea Cuervo1, Julio Ramírez3, Juan Cañete1, Jose Gomez Puerta1 and Raimon Sanmarti1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 3Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain

    Background/Purpose:  Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…
  • Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections

    Kathrine Lederballe Grøn1, Elizabeth V. Arkema2, Bente Glintborg1, Frank Mehnert3, Mikkel Østergaard4, Lene Dreyer5, Mette Nørgaard3, Niels Steen Krogh6, Johan Askling7 and Merete Lund Hetland8, 1The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, 2Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 3Aarhus University Hospital, Clinical Epidemiological Department, Aarhus, Denmark, 4The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, 5Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, 6ZiteLab ApS, Copenhagen, Denmark, 7Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 8DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark

    Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…
  • Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting

    Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors

    Hung Trinh and Darren Tabechian, Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…
  • Abstract Number: 237 • 2018 ACR/ARHP Annual Meeting

    The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis

    Adam Berlinberg1, Jawad Bilal2, Abdullah Alhifany3, Warda Faridi4 and C. Kent Kwoh5, 1Department of Internal Medicine, University of Arizona, Tucson, AZ, 2Internal Medicine, University of Arizona, Tucson, AZ, 3Department of Pharmacy, University of Arizona, Tucson, AZ, 4Department of Hematology/Oncology, University of Arizona, Tucson, AZ, 5Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ

    Background/Purpose: Interleukin (IL) inhibitors are increasingly being used for rheumatologic diseases. There are many controlled clinical trials assessing the efficacy of IL inhibitors, but there…
  • Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting

    Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database

    Eishi Uechi1,2 and Kiyohide Fushimi2, 1Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, 2Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

    Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
  • Abstract Number: 343 • 2018 ACR/ARHP Annual Meeting

    Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice

    Dmitriy Cherny1, Najia Shakoor2, Todd Beck3 and Sonali Khandelwal4, 1Internal Medicine, Rush University Medical Center, Chicago, IL, 2Division of Rheumatology, Rush University Medical Center, Chicago, IL, 3Bioinformatics, Rush University Medical Center, Chicago, IL, 4Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Patients with rheumatologic disorders often require immunosuppression (e.g. DMARDs, biologics, or high doses of prednisone). These patients are at increased risk for infections. While…
  • Abstract Number: 1516 • 2018 ACR/ARHP Annual Meeting

    Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance

    Naoto Tamura1, Masataka Kuwana2, Tatsuya Atsumi3, Syuji Takei4, Masayoshi Harigai5, Takao Fujii6, Hiroaki Matsuno7, Tsuneyo Mimori8, Shigeki Momohara9, Kazuhiko Yamamoto10, Yoshinari Takasaki11, Kazuto Nomura12, Yutaka Endo12, Tomohiro Hirose12, Yosuke Morishima12, Naonobu Sugiyama12, Noritoshi Yoshii12 and Michiaki Takagi13, 1Juntendo University, Tokyo, Japan, 2Nippon Medical School, Tokyo, Japan, 3Hokkaido University, Sapporo, Japan, 4Medical Center for Children, Kagoshima, Japan, 5Tokyo Women’s Medical University, Tokyo, Japan, 6Wakayama Medical University, Wakayama, Japan, 7Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 8Kyoto University, Kyoto, Japan, 9Hakkeikai Inc Medical Institution, Shizuoka, Japan, 10The University of Tokyo, Tokyo, Japan, 11Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, 12Pfizer Japan Inc, Tokyo, Japan, 13Yamagata University Faculty of Medicine, Yamagata, Japan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Previously, the efficacy and safety of tofacitinib were demonstrated in patients (pts)…
  • Abstract Number: 520 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program

    Lucia C. Domínguez-Casas1, Paz Rodríguez-Cundín2, Vanesa Calvo-Río3, Nuria Vegas-Revenga3, Virginia Portilla4, F. Antolin2, M. Rebollo-Rodrigo2, Alfonso Corrales1, Diana Prieto Peña3, Monica Calderón Goercke3, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain, 3Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Rheumatoid arthritis(RA) patients are at increased risk of infections particularly respiratory infections. These may be augmented due to RA itself and to immunosuppressive durgs,…
  • Abstract Number: 1524 • 2018 ACR/ARHP Annual Meeting

    Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Maria A. Lopez-Olivo1, Jean Tayar2, Natalia Zamora3, Gregory Pratt4 and Maria Suarez-Almazor5, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, 3Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 5Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX

    Background/Purpose: Two JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology